TBPH — Theravance Biopharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1583107 ·
Last close
$17.03
Market Cap
$884.18M
52W High
$17.07
52W Low
$17.02
ADV30
3,347,832
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 20,731,000 | — | 1,843,000 | -5,898,000 | 469,770,000 | 219,766,000 | 180,065,000 |
| Mar 2026 | 17,699,000 | — | -5,850,000 | -4,933,000 | 472,313,000 | 288,101,000 | 181,719,000 |
| Dec 2025 | 45,891,000 | — | 20,011,000 | 61,024,000 | 485,570,000 | 167,806,000 | 188,847,000 |
| Sep 2025 | 19,990,000 | — | -6,455,000 | 3,615,000 | 415,460,000 | 174,773,000 | 182,779,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$268,781,000
Investing CF
$-83,323,000
Financing CF
$-7,971,000
CapEx
$-198,000
Dividends Paid
—
Buybacks
$-8,978,000
EPS Diluted TTM
$2.20
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-864,560,000
Inventory
—
Receivables
$15,584,000
ST Investments
$106,565,000
EBIT TTM
$138,733,000
Pretax Income TTM
$136,915,000
Interest Exp TTM
$1,818,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$104,311,000
EBITDA
$11,102,000
Free Cash Flow
$5,300,875
Enterprise Value
$534,050,016
Total Cash
$387,656,992
Total Debt
$38,569,000
Shares Out
51,918,754
Trailing EPS
$1.04
Book Value
$5.58
ROE
20.9%
ROA
1.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 107,464,000 | -3,602,000 | 105,895,000 | 485,570,000 | 188,847,000 | 296,723,000 | 238,541,000 |
| Dec 2024 | 64,381,000 | -42,436,000 | -56,418,000 | 354,161,000 | 178,616,000 | 175,545,000 | -11,535,000 |
| Dec 2023 | 57,424,000 | -53,292,000 | -55,193,000 | 381,999,000 | 169,004,000 | 212,995,000 | -26,997,000 |
| Dec 2022 | 51,346,000 | -79,119,000 | 872,132,000 | 607,400,000 | 165,600,000 | 441,800,000 | -186,991,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$1.27
Max Pain — expiry 2027-03-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $17.50 · spot: $17.03 · call volume: 110 · put volume: 285
Expected Move to 2027-03-19:
±$0.52
(3.05%) —
implied range
$16.51 –
$17.55
· ATM straddle on $17.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ARDX | ARDELYX, INC. | $883.00M | $3.42 | — |
| CYRX | Cryoport, Inc. | $881.80M | $17.41 | — |
| RIGL | RIGEL PHARMACEUTICALS INC | $900.00M | $48.18 | — |
| ANL | Adlai Nortye Group Ltd. | $912.15M | $15.53 | — |
| JBIO | Jade Biosciences, Inc. | $917.07M | $14.42 | — |
News headlines (Yahoo Finance, 1h cache)
Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue?
2026-09-09 15:30 · Yahoo
Zymeworks agrees to buy Theravance Biopharma for $929m
2026-06-30 08:26 · Yahoo
Sector Update: Healthcare Stocks Higher Late Afternoon
2026-06-29 19:59 · Yahoo
Zymeworks To Buy Theravance Biopharma In $929M Deal – A Look At What This Deal Means For TBPH Shareholders
2026-06-29 12:44 · Yahoo
Zymeworks to Acquire Theravance Biopharma in $929 Million Deal
2026-06-29 10:19 · Yahoo
THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT
2026-06-29 10:00 · Yahoo
Theravance, after clinical setbacks, agrees to $929M buyout
2026-06-29 08:42 · Yahoo
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
2026-09-28 10:00 · Yahoo
Zymeworks Completes Acquisition of Theravance Biopharma
2026-09-23 20:01 · Yahoo
Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-10 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.